Charles River Laboratories International, Inc. $CRL Shares Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 371.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,506 shares of the medical research company’s stock after purchasing an additional 48,455 shares during the quarter. New York Life Investment Management LLC owned 0.13% of Charles River Laboratories International worth $18,145,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its position in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after purchasing an additional 210,260 shares in the last quarter. Bank of America Corp DE raised its position in shares of Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after buying an additional 54,500 shares in the last quarter. Amundi raised its position in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after buying an additional 492,301 shares in the last quarter. Van Berkom & Associates Inc. raised its position in shares of Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after buying an additional 50,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock valued at $59,044,000 after buying an additional 142,716 shares during the period. Institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Shannon M. Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the transaction, the director directly owned 1,438 shares of the company’s stock, valued at approximately $410,175.12. The trade was a 28.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 63,352 shares of company stock worth $20,291,281 over the last three months. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Robert W. Baird upped their target price on Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Finally, Zacks Research cut Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and an average price target of $308.17.

Check Out Our Latest Research Report on CRL

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $342.81 on Thursday. The company has a 50 day moving average of $309.32 and a 200-day moving average of $227.05. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $379.63. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. The company has a market cap of $16.43 billion, a PE ratio of 376.71, a price-to-earnings-growth ratio of 3.13 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.12. The business had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. During the same quarter last year, the business posted $2.43 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

See Also

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.